

FOLLOWUS
1. 1Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China;
2. 2Department of Pharmacy, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China;
**Corresponding author Tel: 86-10-69156073, E-mail: ljjxmc@163.com
Received:18 June 2014,
Published Online:20 February 2015,
Published:2015-02
Scan QR Code
Wen Jin, Li Han-zhong, Ji Zhi-gang, et al. Effects of Sunitinib Malate on Growth of Human Bladder Transitional Cell Line T24
Objective
To investigate the growth-inhibitory effect of sunitinib malate on human bladder transitional cell carcinoma (TCC)
in vitro
.
Methods
Human bladder TCC cell line T24 was cultured and exposed to graded concentrations of sunitinib malate for 72 hours
in vitro
to determine the sensitivities to drug. Cell viability was measured by MTT assay. Cell apoptotic morphology was observed by fluorescence microscope following DAPI staining. Band expressions of Fas
Fas ligand
poly (ADP-ribose) polymerase (PARP) and β-actin were analyzed by Western blot. Wound healing process of T24 cells exposed to sunitinib malate was assayed.
Results
Sunitinib malate exerted a concentration-dependent and time-dependent inhibitory effect on the T24 cell lines. Fluorescence microscopy showed that small vacuoles appeared in the nuclei of T24 cells and the vacuoles were bigger with higher drug concentrations. The expressions of Fas ligand and PARP in T24 cells treated with sunitinib malate exhibited a concentration-dependent increase. Moreover sunitinib malate suppressed the wound healing process in a concentration-dependent manner.
Conclusion
Sunitinib malate exerted marked inhibitory activity against bladder cancer cell line T24.
Ballas MS , Chachoua A. Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC. Onco Targets Ther 2011 ; 4 : 43 - 58 .
Petrillo M , Scambia G , Ferrandina G. Novel targets for VEGF-independent anti-angiogenic drugs. Expert Opin Investig Drugs 2012 ; 21 : 451 - 72 .
Motzer RJ , Rini BI , Bukowski RM , et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006 ; 295 : 2516 - 24 .
Tran TA , Kinch L , Peña-Llopis S. Platelet-derived growth factor/vascular endothelial growth factor receptor inactivation by sunitinib results in Tsc1/Tsc2-dependent inhibition of TORC1. Mol Cell Biol 2013 ; 33 : 3762 - 79 .
Socinski MA , Novello S , Brahmer JR , et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008 ; 26 : 650 - 6 .
Wu CL , Ping SY , Yu CP , et al. Tyrosine kinase receptor inhibitor-targeted combined chemotherapy for metastatic bladder cancer. Kaohsiung J Med Sci 2012 ; 28 : 194 - 203 .
Kim S , Ding W , Zhang L , et al. Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: A review of clinical trials. Onco Targets Ther 2014 ; 12 : 719 - 28 .
Szarvas T , Jäger T , Droste F , et al. Serum levels of angiogenic factors and their prognostic relevance in bladder cancer. Pathol Oncol Res 2009 ; 15 : 193 - 201 .
Publicity Resources
Related Articles
Related Author
Related Institution
京公网安备11010802024621